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Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an ultra-rare
metabolic autosomal recessive disease, caused by mutations in the nuclear gene
TYMP which encodes the enzyme thymidine phosphorylase. The resulting enzyme
deficiency leads to a systemic accumulation of the deoxyribonucleosides thymidine
and deoxyuridine, and ultimately mitochondrial failure due to a progressive acquisition
of secondary mitochondrial DNA (mtDNA) mutations and mtDNA depletion. Clinically,
MNGIE is characterized by gastrointestinal and neurological manifestations, including
cachexia, gastrointestinal dysmotility, peripheral neuropathy, leukoencephalopathy,
ophthalmoplegia and ptosis. The disease is progressively degenerative and leads to
death at an average age of 37.6 years. As with the vast majority of rare diseases,
patients with MNGIE face a number of unmet needs related to diagnostic delays, a
lack of approved therapies, and non-specific clinical management. We provide here
a comprehensive collation of the available knowledge of MNGIE since the disease
was first described 42 years ago. This review includes symptomatology, diagnostic
procedures and hurdles, in vitro and in vivo disease models that have enhanced our
understanding of the disease pathology, and finally experimental therapeutic approaches
under development. The ultimate aim of this review is to increase clinical awareness
of MNGIE, thereby reducing diagnostic delay and improving patient access to putative
treatments under investigation.
Keywords: MNGIE, thymidine phosphorylase, mitochondrial disease, rare disease, deoxyribonucleoside, TYMP,
mitochondrial DNA, mitochondrial neurogastrointestinal encephalomyopathy
DISEASE NAME AND SYNONYMS
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE, Online Mendelian inheritance
in Man #603041, Genome Database accession #9835128) is a fatal inherited metabolic
disorder caused by mutations in a nuclear gene controlling the metabolism of pyrimidine
deoxyribonucleosides and indirectly influencing the replication and expression of the
mitochondrial genome (Nishino et al., 1999; Hirano et al., 2004b). In the past, the disorder has
also been referred to as:
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• Congenital oculoskeletal myopathy
• Mitochondrial myopathy with sensorimotor polyneuropathy,
ophthalmoplegia, and pseudo-obstruction (MEPOP)
• Mitochondrial neurogastrointestinal encephalopathy
syndrome
• Myoneurogastrointestinal encephalopathy syndrome
• Chronic intestinal pseudo-obstruction with myopathy and
ophthalmoplegia
• Polyneuropathy, ophthalmoplegia, leukoencephalopathy and
intestinal pseudo-obstruction (POLIP);
• Oculogastrointestinal encephalopathy syndrome;
Oculogastrointestinal muscular distrophy (OGIDM)
• Thymidine phosphorylase deficiency
HISTORY
The condition was first described in 1976 by Okamura
et al., who reported a 22-year old cachectic man experiencing
ptosis, ophthalmoplegia, dysphagia and myopathy. Histological
findings revealedmitochondrial abnormalities in skeletal muscles
and liver cells. The authors recognized that the condition
exhibited familial tendencies and therefore proposed the term
congenital oculoskeletal myopathy to describe the disorder
(Okamura et al., 1976). Analogous patients with ocular,
neurological, skeletal, and gastrointestinal involvement were
additionally described in the literature, and Bardosi et al.
also reported leukoencephalopathy in a patient with a history
of extraocular and skeletal myopathy and gastrointestinal
symptoms (Anuras et al., 1983; Ionasescu, 1983; Ionasescu et al.,
1983, 1984; Bardosi et al., 1987; Faber et al., 1987; Simon
et al., 1990). In 1994, Hirano et al. conducted a systematic
review of all reported cases of the condition and proposed
the current nomenclature mitochondrial neurogastrointestinal
encephalomyopathy (MNGIE), which highlighted the central
features of this mitochondrial disorder (Hirano et al., 1994). The
etiology was only elucidated in 1999, when the condition was
attributed to a deficiency in thymidine phosphorylase, E.C.2.4.2.4
(Nishino et al., 1999).
MOLECULAR ETIOLOGY
Mutations in the TYMP gene and a subsequent deficiency in
thymidine phosphorylase activity are the causative factors in
the pathogenesis of MNGIE. Thymidine phosphorylase is also
referred to as gliostatin and platelet derived-endothelial cell
growth factor (PD-ECGF). Structurally the peptide is composed
of two subunit homodimers each with a molecular weight of
∼50 kilodaltons (Norman et al., 2004). Thymidine phosphorylase
catalyses the reversible phosphorylation of thymidine (also
known as deoxythymidine) and deoxyuridine to 2-deoxyribose
1-phosphate and their respective bases, thymine and uracil,
Figure 1 (Nishino et al., 1999). Thymidine phosphorylase has a
pivotal role in the nucleoside salvage metabolic pathway, and in
the recycling of pyrimidine bases by regulating the availability
of thymidine for DNA biosynthesis (Nishino et al., 1999; Levene
et al., 2013).
FIGURE 1 | Reactions catalysed by thymidine phosphorylase.
Mitochondrial deoxyribonucleoside pools are maintained by
both the cytoplasmic de novo pathway and the salvage pathway
located within the mitochondrion, Figure 2. In proliferating
cells, the major source of mitochondrial deoxyribonucleotide
diphosphates originates from the cytoplasmic de novo pathway,
whereby a transporter located in the mitochondrial membrane
transports the deoxyribonucleotide triphosphates (dNTPs)
synthesized in the cytosol into the mitochondrial matrix for the
synthesis of mtDNA. In quiescent cells (such as muscles and
neurons) the cytoplasmic de novo pathway is no longer required
for nuclear DNA replication and is thus down-regulated due
to a reduction in ribonucleotide reductase activity, leading to a
marked reduction in cytosolic dNTP pools (Rötig and Poulton,
2009). mtDNA synthesis is not limited to the S-phase of the cell
cycle and mitochondria are continuously replicating, even in
post-mitotic cells. Therefore, a constant supply of nucleotides
is essential for the maintenance of the mitochondrial genome
and hence the salvage pathway becomes important. The loss of
function of thymidine phosphorylase leads to an enhancement
of thymidine salvage through the action of thymidine kinase 2
(TK2) which is constitutively expressed in the mitochondria.
Of note, thymidine kinase 1 (TK1) is upregulated only in
proliferating cells. TK2 converts thymidine to thymidine
monophosphate, as well as deoxyuridine and deoxycytidine to
their respective monophosphate nucleotides, and is therefore
believed to contribute to the generation of the deoxynucleotide
pool imbalances in the mitochondria (Nishino et al., 1999;
Hirano et al., 2004b).
Since thymidine phosphorylase is crucial in the pyrimidine
metabolic pathway for the catabolism of thymidine, its
dysfunction compromises the deoxyribonucleoside pool balance.
It is observed that the tissues affected in MNGIE are
predominantly post-mitotic (Samsonoff et al., 1997; Nishino
et al., 1999; Pontarin et al., 2006; Zhou et al., 2008;
Balasubramaniam et al., 2014). Consequently, because of the
deoxyribonucleoside pool imbalance, combined with the limited
ability of the mitochondrial DNA polymerase γ to repair
DNA, mtDNA gradually accumulates mutations over time,
which ultimately leads to the failure of mitochondria to
perform oxidative phosphorylation, Figure 3 (Bogenhagen, 1999;
Nishigaki et al., 2004).
In MNGIE, phenotypic manifestations of the disease develop
when a threshold level of mutant mtDNA is reached, which
is generally when more than 80–90% of total mitochondria
are affected (Mazat et al., 2001; Nishigaki et al., 2003). This
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FIGURE 2 | Deoxynucleotide salvage and de-novo synthesis pathways. Abbreviations are as follows: deoxythymidine (dThd), deoxyuridine (dUrd), deoxythymidine
monophosphate (dTMP), deoxythymidine diphosphate (dTDP), deoxynucleotidase 1 (dNT1), thymidine phosphorylase (TP), thymidine kinase 1 (TK1),
deoxynucleotidase 2 (dNT2), nucleotide monophosphate kinase (NMPK), nucleotide diphosphate kinase (NDPK), deoxythymidine triphosphate (dTTP), thymidine
kinase 2 (TK2), DNA polymerase Y (DNA pol Y), nucleotide diphosphate (NDP), ribonucleotide reductase (RNR), deoxyribonucleotide diphosphate (dNDP), and
deoxynucleotide triphosphate (dNTP).
FIGURE 3 | Metabolic defect in MNGIE.
threshold effect and the heteroplasmic nature of mitochondria
(the existence of two ormoremitochondrial genotypes within the
same cell) very likely account for the protracted interval before
the condition manifests and contributes to the heterogeneous
phenotypes observed.
In humans thymidine phosphorylase is abundantly expressed
in blood cells (platelets, macrophages, peripheral lymphocytes,
stromal cells, and reticulocytes), liver, lungs, brain and tissues
of the digestive tract; however it is not expressed in skeletal
muscle, kidneys or adipose tissue (Fox et al., 1995). In addition
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to its enzymatic activity driving the salvage pathway, thymidine
phosphorylase also functions as a signaling molecule playing
an essential role in a number of processes (Li and Yue, 2017).
Thymidine phosphorylase acts as a growth factor with strong
pro-angiogenic effects and is a potent mitogen for endothelial
cells (Miyazono et al., 1987; O’Brien et al., 1996). In addition
it has been demonstrated that thymidine phosphorylase is an
inhibitor of apoptosis (Li and Yue, 2017). Platelets are a major
source of thymidine phosphorylase, and it has been shown that
the protein is involved in platelet activation through exhibiting
a potent pro-thrombotic effect (Miyazono et al., 1987; Li and
Yue, 2017). Moreover, thymidine phosphorylase shows a strong
inhibitory effect on all glial cells and has been demonstrated
to exert a neurotrophic effect on cortical neurons (Asai et al.,
1992a,b; Ueki et al., 1993).
A deficiency in enzymatic activity (<5% of healthy
individuals) results in elevated concentrations of thymidine
and deoxyuridine in tissues and body fluids, which consequently
generate deoxyribonucleoside pool imbalances, leading to
impaired mtDNA replication, and ultimately mitochondrial
failure (Hirano et al., 1994; Spinazzola et al., 2002; Martí
et al., 2003; Valentino et al., 2007). In patients with MNGIE,
deoxyribonucleoside concentrations can reach plasma levels
of 3.9–17.7 µmol/L for thymidine and 5.5–24.4 µmol/L for
deoxyuridine, compared to undetectable levels in healthy
unaffected individuals (Hirano et al., 1998; Martí et al., 2003).
In tissues such as the small intestine, kidney, liver, peripheral
nerve, and occipital white matter, levels in the range of 38–1532
nmoles/g protein for thymidine and 32–728 nmoles/g protein
for deoxyuridine have been reported (Valentino et al., 2007).
Thymidine and deoxyuridine are ultra-filterable, and thus the
systemic accumulation of thymidine and deoxyuridine is further
exacerbated by the efficiency of renal reabsorption of these
deoxyribonucleosides (Okamura et al., 1976; Hirano et al., 1998;
Spinazzola et al., 2002; Garone et al., 2011).
Disease-Causing Mutations
TYMP Mutations
The TYMP gene has been mapped to the chromosomal locus
22q13.32-qter (Hirano et al., 1998; Nishino et al., 1999, 2000).
Since the identification of TYMP as the gene responsible for
MNGIE, 92 different mutations have been reported by the
Human Gene Mutation Database (HGMD Professional 2018.2,
accessed September 2018) (Stenson et al., 2014), including 56
missense/nonsense (Nishino et al., 1999, 2000; Gamez et al., 2002;
Kocaefe et al., 2003; Hirano et al., 2004b; Martín et al., 2004;
Marti et al., 2005; Said et al., 2005; Slama et al., 2005; Carod-
Artal et al., 2007; Schupbach et al., 2007; Monroy et al., 2008;
Massa et al., 2009; Poulton et al., 2009; Baris¸ et al., 2010; Garone
et al., 2011; Nalini and Gayathri, 2011; Scarpelli et al., 2012;
Mihaylova et al., 2013; Suh et al., 2013; Benureau et al., 2014;
Vondrácková et al., 2014; Peedikayil et al., 2015; Wang et al.,
2015; Karyampudi et al., 2016), 13 splice site mutations (Nishino
et al., 1999, 2000; Kocaefe et al., 2003; Szigeti et al., 2004b; Slama
et al., 2005; Laforce et al., 2009; Taanman et al., 2009; Garone
et al., 2011; Libernini et al., 2012; Halter et al., 2015), 13 small
deletions (Nishino et al., 1999, 2000; Blazquez et al., 2005; Slama
et al., 2005; Poulton et al., 2009; Filosto et al., 2011; Garone
et al., 2011; Torres-Torronteras et al., 2011; Halter et al., 2015;
Karyampudi et al., 2016), 6 small insertions (Nishino et al., 1999;
Gamez et al., 2002; Hirano et al., 2004b; Kintarak et al., 2007;
Poulton et al., 2009; Cardaioli et al., 2010), 2 small indels (Garone
et al., 2011; Libernini et al., 2012) 1 gross insertion (Wang et al.,
2017) and 1 gross deletion (Vondrácková et al., 2014). These
mutations have beenmapped to either exonic or intronic regions,
with some identified as benign and some as pathogenic variants.
Figure 4 summarizes the known pathogenic variants associated
with MNGIE, based on their classification and location on the
TYMP gene.
The mutation distribution suggests founder effects for some
mutations such as c.866A>G in Europeans and c. 518T>G in
individual from the Dominican Republic (Garone et al., 2011).
Effect on Mitochondrial DNA
The secondary mtDNA mutations reported in MNGIE,
are caused by the toxic accumulations of thymidine and
deoxyuridine, because of the nuclear TYMP mutations.
These secondary mutations have been identified as mtDNA
deletions, depletion and misincorporations. Acquired secondary
mitochondrial mutations appear to be conserved in most
cases, with 86% of detected mutations being T>C transitions
preceded by a short run of As. This can be explained by a
competition between guanosine monophosphate (GMP) and
adenosine monophosphate (AMP) for incorporation opposite to
a thymine residue on the template DNA. After the occurrence of
misincorporations, elevated thymidine triphosphate (TTP) levels
accelerate polymerase γ exonuclease removal of mismatches,
so that the T is switched to C during mtDNA replication; these
mutations ultimately lead to failure of oxidative phosphorylation
(Nishigaki et al., 2003). Certain mtDNA genes appear to be
hotspots for mutations in MNGIE, such as the ND5 gene which
is prone to multiple deletions (Nishigaki et al., 2004). Gonzalez-
Vioque et al. proposed a hypothesis for the mtDNA depletion
observed in MNGIE, suggesting that mitochondrial replication is
not affected by the accumulation of nucleosides per se, but rather
by the secondary depletion of deoxycytidine stemming from an
increase in TTP pools, thus limiting its availability for mtDNA
biosynthesis (González-Vioque et al., 2011).
EPIDEMIOLOGY
MNGIE is an ultra-rare disorder with a European incidence of
< 1 in a million, with Orphanet estimating the prevalence to
be 1–9 in 1,000,000 world-wide (Orphanet, 2018). Estimated
epidemiological data is largely confined to various case reports or
case series from several groups over the last two decades. Halter
et al. (2010), quotes a personal communication from M. Hirano
of fewer than 200 identified patients world-wide (Halter et al.,
2010). In the only systematic study of epidemiology of the disease,
a minimum prevalence estimate of ∼0.15 per 1,000,000 was
established in a prospective Italian survey in the Emilia-Romagna
region (D’Angelo et al., 2016).
MNGIE is distributed amongst a widely distributed and
ethnically diverse population including Hispanics, Americans,
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FIGURE 4 | Pathogenic TYMP gene mutations (NM_001113755.2; NP_001107227) in exonic and intronic regions. Protein changes, where known are indicated in red
font.
Western Europeans, Jamaicans, Ashkenazi Jewish, Middle
Eastern, and Canadians (Nishino et al., 2001; Hirano et al.,
2004b; Kintarak et al., 2007; Borhani Haghighi et al., 2009;
Baris¸ et al., 2010). An ethnic predisposition has yet to
be established. However since the pathology is inherited
in an autosomal recessive fashion, populations in which
consanguineous relationships are common are more at risk
(Walia et al., 2006).
It is currently not possible to be confident about stating
the prevalence of MNGIE as the disorder is appreciably under-
diagnosed due its multisystem presentation and rarity (Filosto
et al., 2011; Scarpelli et al., 2012). The condition is not familiar
to a majority of clinicians, and patients typically undergo referral
to several different specialities over a protracted period of time
before a diagnosis is achieved. The diagnosis is often not made
until after the death of one or two family members with similar
symptomatology.
CLINICAL DESCRIPTION
MNGIE is a relentlessly progressive and degenerative disease,
causing significant morbidity. Although the clinical presentation
of MNGIE is homogeneous, it is characterized by a complex
clinical picture, with the involvement of multiple organ
systems to differing extents in different individuals, Table 1.
The mean age mortality of 37.5 years (Nishino et al.,
2000). Based on a review of the literature, we propose
a classification of the major and minor clinical features
of MNGIE. The major clinical features for the diagnosis
of MNGIE are severe gastrointestinal dysmotility, cachexia,
peripheral neuropathy, ocular symptoms, and asymptomatic
diffuse leukoencephalopathy, Figure 5 (Hirano et al., 1994,
2004b; Nishino et al., 2000). Other signs and symptoms represent
a minor clinical criterion for the diagnosis of the disease,
including certain neurological, muscular, cardiac and endocrine
features, as well as other sporadicmanifestations discussed below.
Onset of Symptoms
The onset of MNGIE disease is usually between the first and
second and decade of life, with an average age of onset at 18.5
years (Nishino et al., 2001; Garone et al., 2011); however, reported
age of onset may not be accurate due to delay in diagnosis
stemming from the subtlety of non-specific symptoms (Hirano
et al., 1998). A few cases of late onset beyond the third decade
and as late as the fifth decade have been reported, which were
associated with compound heterozygous TYMP mutations and
a less severe phenotype characterized by a partial reduction of
thymidine phosphorylase activity (Marti et al., 2005; Massa et al.,
2009).The earliest reported age of onset is five months of age
(Garone et al., 2011). However, in a majority of patients, the first
insidious symptoms manifest during childhood (Garone et al.,
2011).
Major Clinical Criteria for Diagnosis
Gastrointestinal Features
Gastrointestinal dysmotility is one of the most common
features of MNGIE, with patients manifesting intestinal pseudo-
obstruction, abdominal cramps, enteric bacteria overgrowth,
nausea, vomiting, borborygmy, diarrhea, dysphagia, and
gastroparesis (Garone et al., 2011). Gastrointestinal dysfunctions
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TABLE 1 | List of clinical features reported in MNGIE.
Features Sign/symptom Frequency
Neurological Peripheral neuropathy +++
Hearing loss ++
Leukoencephalopathy +++
Seizures +
Migraine +
Anxiety +
Depression +
Cognitive dysfunction +
Dementia +
Mental retardation +
Memory loss +
Ataxia +
Trigeminal neuralgia +
Neuro-ophthalmic Ophthalmoplegia +++
Ophthalmoparesis +++
Ptosis +++
Glaucoma +
Pigmentary retinopathy +
Muscular Myopathy ++
Red ragged fibers ++
Gastrointestinal Intestinal pseudo-obstruction ++
Constipation ++
Abdominal cramps ++
Nausea +++
Emesis +++
Borborygmy ++
Diarrhoea ++
Dysphagia +++
Gastroparesis +++
Cachexia +++
Weight loss +++
Oesophageal varices ++
Megacolon +
Diverticulosis ++
Intestinal perforation ++
Peritonitis ++
Hepatic steatosis ++
Hepatomegaly +
Cirrhosis +
Endocrine/Metabolic Diabetes ++
Hyperlipidaemia ++
Hypertriglyceridemia ++
Hypergonadotropic
hypogonadism
+
Cardiac Long QT +
Supraventricular tachycardia +
Ventricular hypertrophy +
Mitral valve prolapse +
Reproductive Ovarian failure +
Erectile dysfunction +
Amenorrhea +
(Continued)
TABLE 1 | Continued
Features Sign/symptom Frequency
Haematological Anaemia +
Dermatological Psoriasis +
Developmental Short stature ++
+++ indicates a major diagnostic feature of MNGIE, ++ a common clinical presentation
and + a sporadic feature.
eventually lead to malnutrition, cachexia and severe weight loss
with averages of 15Kg loss being reported (Nishino et al., 1999).
Regardless of the gastrointestinal irregularities, patients appear
to have normal serum levels of vitamins E, B12 and folate (Holt
et al., 1990; Mueller et al., 1999). Patients with MNGIE often
have a frail and slender physique with reduced muscle mass. It is
unclear whether the gastrointestinal involvement is the result of
intestinal smooth muscle dysfunction caused by mitochondrial
defects or whether damage to the enteric nervous system is
primarily responsible (Verma et al., 1997). It is recognized
that as the disease progresses, the gastrointestinal symptoms
are exacerbated, with patients dying from severe malnutrition
and gastrointestinal complications such as esophageal varices,
megacolon, diverticulosis, bowel perforations, peritonitis, and
bacterial overgrowth (Martinez-Garcia et al., 2001; Aksoy et al.,
2005; Moran et al., 2008; Granero Castro et al., 2010; Scarpelli
et al., 2012; Dreznik et al., 2014; Kalkan et al., 2015; Finsterer and
Frank, 2017). Patients exhibiting hepatopathies have also been
reported, including cases of hepatic steatosis, hepatomegaly,
increased transaminases and cirrhosis (Schupbach et al., 2007;
Garone et al., 2011; Finkenstedt et al., 2013).
Peripheral Neuropathy
In the peripheral nervous system, MNGIE results in neuropathy
(Garone et al., 2011). This manifests as numbness, paraesthesia
(tingling sensation), foot drop and limb weakness (Garone et al.,
2011). The neuropathy has been shown to be demyelinating in all
cases, with half the reported cases also having axonal neuropathy
(Garone et al., 2011). Ultra-structurally, nerve biopsies reveal
segmental demyelination, myelin sheath abnormalities, and
axonal degeneration and depletion (Bedlack et al., 2004).
Unilateral or bilateral foot drop and clawed hands may also be
observed (Garone et al., 2011). The neuropathy is characterized
by decreased motor and sensory nerve conduction velocities,
prolonged F-wave latency and partial conduction block (Bedlack
et al., 2004). The clinical and electrophysiological features may
mimic those of other conditions including chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP) and Charcot-
Marie-Tooth disease (Bedlack et al., 2004; Needham et al., 2007).
Ocular Symptoms
Ocular symptoms such as ptosis and ophthalmoplegia or
ophthalmoparesis are also common neurological findings
in patients with MNGIE (Barboni et al., 2004). Other
uncommon ocular manifestations include reports of mild
myopia, glaucomatous-like features and tilted disc with focal
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FIGURE 5 | Major clinical features of MNGIE. Copyright permission was obtained for the reproduction of images taken from Baris¸ et al. (2010), Filosto et al. (2011),
Scarpelli et al. (2012).
defects of the retinal nerve fibers (Barboni et al., 2004). Rarely,
pigmentary retinopathy can also be observed in patients with
MNGIE (Hirano et al., 1994; Nishino et al., 1999; Aksoy et al.,
2005; Garone et al., 2011).
Leukoencephalopathy
One peculiarity of MNGIE is the typically paucisymptomatic
central nervous system (CNS) involvement. In the majority
of affected individuals, this is identified as white matter
lesions that remain subclinical and visible as a signal change
on Magnetic Resonance Imaging (MRI) scans indicating
progressive leukoencephalopathy (Garone et al., 2011).
Leukoencephalopathy is the hallmark feature of the pathology
and its presence in combination with gastrointestinal and
neuropathic symptoms significantly narrows the differential
diagnosis to MNGIE. The leukoencephalopathy as identified
by MRI, is initially patchy but progressively becomes more
diffuse, appearing as hypointense on T1- and hyperintense
on T2- weighted images and in fluid-attenuated inversion
recovery (FLAIR) and fast spin echo (FSE) T2 sequences
(Garone et al., 2011; Çoban et al., 2013; Scarpelli et al., 2013;
Gramegna et al., 2018). The most involved region of the CNS
in MNGIE is the subcortical white matter. Hyperintensities in
the subcortical U-fibers and occasionally in the corpus callosum
have been reported, alluding to problems in the interhemispheric
communication (Millar et al., 2004; Scarpelli et al., 2013). Areas
less frequently affected include the capsular white matter, and the
white matter in the basal ganglia, thalami, midbrain, pons and
cerebellum (Millar et al., 2004; Barragán-Campos et al., 2005;
Scaglia et al., 2005; Petcharunpaisan and Castillo, 2010). The
reasons why the leukoencephalopathy remains asymptomatic
are yet to be elucidated, however it has been suggested that
hyperintense lesions observed by MRI could be the result of
alterations in the brain microvasculature causing vasogenic
oedema and glial dysfunctions (Szigeti et al., 2004a; Scarpelli
et al., 2013; Gramegna et al., 2018). Whether there are subtle
neuropsychiatric or cognitive changes associated with the
leukoencephalopathy remains an open question.
Minor Clinical Criteria for Diagnosis
Other Central Nervous System Associated Features
A growing body of evidence suggests that the CNS involvement
in MNGIE could be more symptomatic than initially described
(Garone et al., 2011). For instance, in a number of patients,
cases of seizures, including generalized tonic-clonic seizures, have
been reported (Walia et al., 2006; Yavuz et al., 2007; Garone
et al., 2011). Garone et al. indicated that six patients with
MNGIE from their study cohort of 102 complained of headache,
and similarly an independent study evaluating the frequency of
migraine in mitochondrial diseases identified one patient with
MNGIE suffering from episodes of cephalgia (Garone et al.,
2011; Vollono et al., 2018). Psychiatric manifestations have been
noted inMNGIE, with patients reporting anxiety and depression,
although it remains unclear whether these are secondary to
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the psychological aspect of coping with a terminal debilitating
condition (Garone et al., 2011; Scarpelli et al., 2013). Cases
of patients with dementia and cognitive dysfunction have also
been reported, with one patient also showing mental retardation
(Hirano et al., 1994; Carod-Artal et al., 2007; Garone et al.,
2011). Problems with memory, concentration and visuospatial
orientation have also been observed in some patients (Borhani
Haghighi et al., 2009). Ataxia is also occasionally observed in
MNGIE (Hirano et al., 1994). A case study reported trigeminal
neuralgia in one patient with MNGIE, and the authors suggested
that this could be ascribable to demyelinating lesions in the
trigeminal intrapontine fibers within the brain stem, as observed
in MRI images, in an analogous way to that observed in patients
with multiple sclerosis (Peker and Necmettin Pamir, 2005).
Sensorineural Hearing Impairment
Hearing loss is reported as one of the most common neurologic
features in patients with MNGIE(Hirano et al., 2004b; Baris¸ et al.,
2010; Cardaioli et al., 2010; Garone et al., 2011). For instance,
the study by Garone et al. reported that 39% of patients, from
a cohort of 102, presented with anacusis (Garone et al., 2011).
Hearing loss appears to be sensorineural and is not common
during the presentation of the first symptoms, however it is more
prominent in the later stages of the disease (Hirano et al., 2004b).
Muscular Features
Thymidine phosphorylase is not physiologically expressed in
skeletal muscle, but the muscle from patients with MNGIE
shows alterations in mtDNA, COX–deficient and ragged red
fibers and respiratory chain enzymatic defects (Yoshimura
et al., 1990; Hirano et al., 1994; Nishino et al., 1999). This
observation has in the past been referred to as the “muscle
paradox” (Nishino et al., 1999; Hirano et al., 2004b); it is
now known that the pathological involvement of this tissue is
due to systemic accumulations of the pyrimidine nucleosides
rather than an absence of thymidine phosphorylase activity itself
(Nishino et al., 1999). In healthy individuals, the absence of
detectable thymidine and deoxyuridine suggests that thymidine
phosphorylase regulates intracellular and extracellular levels
of these deoxyribonucleosides. It is believed that the platelets
and other blood cells, as wells as tissues rich in thymidine
phosphorylase activity regulate these levels, especially in those
tissues which lack thymidine phosphorylase (Nishino et al., 1999,
2000; Spinazzola et al., 2002; Hirano et al., 2004a). Of note, some
patients with MNGIE do not display a primary skeletal muscle
involvement (Szigeti et al., 2004b; Cardaioli et al., 2010).
Endocrine and Metabolic Dysfunctions
Sporadically, there have been reports of MNGIE patients
presenting endocrine and metabolic dysfunctions, including
endocrine/exocrine pancreatic insufficiency, diabetes, amylase
increases and glucose intolerance (Garone et al., 2011). Alteration
in plasma lipid profiles have also been observed in patients
presenting severe hyperlipidaemia and hypertriglyceridemia
(Baris¸ et al., 2010; Garone et al., 2011). A reduction of
mitochondrial function is likely to be an important contributor
to the lipid accumulation and insulin resistance. Furthermore,
there have been two reports of patients with MNGIE manifesting
hypergonadotropic hypogonadism (Carod-Artal et al., 2007;
Kalkan et al., 2012).
Immunodeficiency
In patients with MNGIE, gastrointestinal dysfunctions can lead
to a dysbiosis of the intestinal microbiome, and current research
has shown that alterations in the gut flora can impact on
systemic adaptive immune responses (Round and Mazmanian,
2009; Filosto et al., 2011; van den Elsen et al., 2017). Additionally,
patients often manifest complications, which include diverticular
ruptures, intestinal perforations and aspiration pneumonia
which expose individuals to infections that can present fatal
outcomes. Recurrent infections have been reported, with these
adverse events contributing to the worsening of the symptoms
and prognosis (Garone et al., 2011). In one case report, a patient
was described with bacterial endocarditis, suggesting the immune
system may be suppressed in MNGIE (Yolcu et al., 2014).
Cardiac Complications
Cardiac manifestations are usually asymptomatic in MNGIE,
although the study of Garone et al., reported occasional cardiac
complications, including a prolonged QT interval, cardiac arrest
and supraventricular tachycardia (Garone et al., 2011; El-Hattab
and Scaglia, 2016). Abnormal ECG has also been reported in a
number of patients, with individuals displaying left ventricular
hypertrophy and bundle branch block (Hirano et al., 2004b).
A study also described cardiac dysfunction in affected twins,
presenting mitral valve prolapse and systolic heart murmurs
(Schupbach et al., 2007). Another case study reported the death
of two brothers due to cardiomyopathy (Borhani Haghighi et al.,
2009).
Other Sporadic Features
From a review of the literature, other non-specific manifestations
have been reported, which are sporadic and are not clearly
attributable to MNGIE or the secondary ailments of the disease.
Amongst these less common manifestations, patients have been
reported with ovarian failure (Borhani Haghighi et al., 2009),
anemia, amenorrhea (Gamez et al., 2002; Garone et al., 2011) and
psoriasis (Garone et al., 2011). Short stature has been reported in
a number of patients (Hirano et al., 1994; Debouverie et al., 1997;
Papadimitriou et al., 1998; Gamez et al., 2002; Martín et al., 2004;
Garone et al., 2011). Furthermore, a case of erectile dysfunction
has been diagnosed in a young male MNGIE patient (Schupbach
et al., 2007).
Histopathology
Skeletal muscle biopsy may show ragged-red fibers (due
to abnormal proliferation of mitochondria in response
to defective oxidative phosphorylation), ultra-structurally
abnormal mitochondria, and abnormalities of both mtDNA
and mitochondrial electron transport chain enzymes activities
on enzyme analysis (Papadimitriou et al., 1998). However, it
is important to note that ragged-red fibers are not always seen
in MNGIE, as some patients do not display this histological
abnormality (Szigeti et al., 2004b; Cardaioli et al., 2010).
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Rectal biopsies show eosinophilic cytoplasmic inclusions
in the submucosal ganglion cells (Perez-Atayde et al., 1998).
Duodenal biopsies show focal muscle atrophy or absence, with
increased nerve numbers, serosal granulomas and focal loss of
Auerbach’s plexus with fibrosis (Teitelbaum et al., 2002). Also,
mtDNA depletion, mitochondrial proliferation and smooth cell
atrophy are observed in the external layer of the muscularis
propria in the stomach and small intestine (Giordano et al., 2006).
Loss of interstitial cells of Cajal in the small bowel has also been
reported (Zimmer et al., 2009; Yadak et al., 2018a).
Histopathological studies post mortem have failed to identify
demyelination, neuronal loss or glial scarring in the areas of the
brain white matter affected, as visualized by MRI (Szigeti et al.,
2004a; Gramegna et al., 2018). However, the presence of albumin
in the cytoplasm of reactive astrocytes was observed suggesting
functional blood brain barrier alterations and consequent
vasogenic oedema as a cause of leukoencephalopathy (Szigeti
et al., 2004a). Furthermore, a mild perivascular gliosis was also
observed in immunohistochemical analyses (Gramegna et al.,
2018).
Ultra-structurally, peripheral nerve fibers show
demyelination, and abnormal mitochondrial in Schwann
cells (Hirano et al., 1994; Bedlack et al., 2004; Said et al., 2005). In
addition to loss of myelinated fibers, nerve biopsies demonstrate
mild perineural thickening, segmental demyelination, variation
in internodal length and evidence of axonal regeneration (Hirano
et al., 1994).
GENOTYPE-PHENOTYPE RELATIONSHIP
The primary clinical manifestations of MNGIE are well
characterized and homogeneous (Cardaioli et al., 2010).
However, one of the problematic aspects of MNGIE is that
specific TYMP mutations do not necessarily correlate with
distinct phenotypes, and therefore it is not possible to anticipate
disease severity, system involvement and age of onset based on
the mutation (Nishino et al., 2000). Indeed, individuals with the
same TYMPmutation do not always exhibit the same phenotype,
resulting in heterogeneity amongst patients. We hypothesize that
clinical heterogeneity in MNGIE could be attributable to mtDNA
heteroplasmy, as observed in other mitochondrial disorders
(Morgan-Hughes and Hanna, 1999). For instance, siblings
harboring the same mutations (435G>A) have been reported
not to display an identical clinical phenotype, with the proband
displaying both neurological and gastrointestinal symptoms,
whereas the sibling had no gastrointestinal involvement (Gamez
et al., 2002).
Some patients have been reported to manifest typical
symptoms of MNGIE without any overt muscular abnormalities
to confirm the diagnosis, suggesting that there might be a
clear genotype-phenotype relationship in patients lacking skeletal
muscle involvement (Szigeti et al., 2004b; Cardaioli et al., 2010).
It is unclear how eachmolecular variant affects the phenotype,
however certain mutations have been associated with less severe
enzyme dysfunction (10–15% residual activity), such as the
266G>A variant, which translates to milder manifestations and
presentation of some of the canonical symptoms and a late onset
of the disease (Marti et al., 2005; Massa et al., 2009).
Although the nervous and gastrointestinal systems are both
affected, some patients display phenotypes characterized by a
notably more prominent involvement of one or the other organ
system (Gamez et al., 2002). The understanding of why one
system is more affected than the other in certain patients remains
unclear.
Furthermore, MNGIE-like manifestations occur in patients
with normal thymidine phosphorylase activity, which are
attributed to mutations in genes other than the TYMP, such as
POLG and RRM2B (Nishino et al., 2001).
Heterozygotes for pathogenic TYMP mutations exhibit only
26–35% thymidine phosphorylase activity in buffy coats, which is
sufficient to prevent the disease and the manifestation of a clear
phenotype (Spinazzola et al., 2002).
DIAGNOSIS
Diagnostic Challenges
The rarity of MNGIE and its multisystem nature contribute
to a complex clinical picture that is often difficult for non-
specialist healthcare professionals to decipher and provide
an early diagnosis (Filosto et al., 2011). This can lead to
diagnostic delays of between 5 and 10 years (Lara et al.,
2007; Taanman et al., 2009). Although confirmation of the
diagnosis by testing for thymidine and deoxyuridine in the
urine and plasma, combined with Sanger sequencing of the
TYMP gene is straightforward, initial identification of this rare
condition often requires a clinical interdisciplinary approach,
leading to diagnostic delays, and unnecessary invasive diagnostic
procedures, such as exploratory surgeries for gastrointestinal
disturbance or unnecessary treatments, such as intravenous
immunoglobulin before the diagnosis is made. A late diagnosis
is often associated with a worse prognosis (Scarpelli et al., 2012;
Çoban et al., 2013). This situation advocates the urgent need for
the early diagnosis of MNGIE. Thus, thymidine phosphorylase
deficiency should be suspected in cases where gastrointestinal
and neurological involvement coexist, particularly where there is
leukoencephalopathy on MRI or abnormalities of ocular motility
(Scarpelli et al., 2012). The symptoms of MNGIE often resemble
other conditions which are usually included in the differential
diagnosis. Frequently, patients are incorrectly diagnosed with
anorexia nervosa, inflammatory bowel disease, Crohn’s disease,
Whipple disease, chronic intestinal pseudo-obstruction, coeliac
disease, chronic inflammatory demyelinating polyneuropathy
and demyelinating forms of Charcot-Marie-Tooth disease (Said
et al., 2005; Needham et al., 2007; Filosto et al., 2011; Garone et al.,
2011; Demaria et al., 2016; Imperatore et al., 2017; Nagata and
Buckelew, 2017; Kucerová et al., 2018). Phenotypes resembling
MNGIE may be seen in patients with other mitochondrial DNA
depletion syndromes including POLG or RRM2B mutations and
Kearns-Sayre syndrome. These are often referred to as pseudo-
MNGIE manifestations (Shaibani et al., 2009; Garone et al.,
2011; Prasun and Koeberl, 2014). More recently two cases of
MNGIE-like patients exhibiting POLG mutations were reported
to manifest leukoencephalopathy and demyelinating peripheral
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neuropathy, which are characteristic not typically observed with
these mutations (Yasuda et al., 2018). Another case study, reports
two patients with a MNGIE-like phenotype exhibiting optic
atrophy associated with a novel POLG mutation affecting the C-
terminal sub-domain of the protein (Felhi et al., 2018).
Current Diagnostic Methods for MNGIE
Thymidine and Deoxyuridine Measurement in Plasma
and Urine
Plasma thymidine and deoxyuridine levels are increased to > 3
µmol/L and > 5 µmol/L, respectively, compared to undetectable
levels in healthy unaffected controls (Martí et al., 2003, 2004).
Urine concentrations of thymidine and deoxyuridine are also
increased (Spinazzola et al., 2002).
TP Activity
An evaluation of thymidine phosphorylase activity is typically
required to complement the measurement of thymidine and
deoxyuridine concentrations in body fluids, or upon the
identification of novel variants of the TYMP gene, or when
clinics do not have access to Sanger sequencing of TYMP.
Thymidine phosphorylase activity in the leukocytes of patients
with MNGIE are severely reduced, showing little (<10% of
healthy unaffected controls) or no activity (Spinazzola et al., 2002;
Martí et al., 2004). Heterozygous carriers of TYMP mutations
have 26 to 35% of residual thymidine phosphorylase activity
but are asymptomatic and have undetectable levels of plasma
thymidine and deoxyuridine (Nishino et al., 1999; Spinazzola
et al., 2002). These data suggest that a 70% reduction in thymidine
phosphorylase activity is insufficient to be pathogenic.
Molecular Genetic Abnormalities
Patients are either homozygous or compound heterozygous for
TYMP mutations and therefore the diagnosis is made by the
detection of biallelic pathogenic variants in the gene (Nishino
et al., 2001). For this reason genetic counseling is fundamental
as the autosomal recessive inheritance translates to a 25% risk
for offspring of carrier parents to be affected, whereas 50% will
be asymptomatic carriers. Cases of MNGIE amongst twins have
been reported, including a triplet in which twomonozygotic pairs
were affected whereas the dizygotic sibling was an asymptomatic
carrier (Schupbach et al., 2007). Similarly, other case studies
have described monozygotic twins carrying the same mutation
and exhibiting the same phenotype (Papadimitriou et al., 1998;
Bedlack et al., 2004). Genetic counseling should bemade available
to affected individuals and their families.
Targeted gene testing for primary TYMP mutations or
more comprehensive genomic analyses for the whole genome
including secondary mtDNA mutations can be used, such
as Sanger or next generation sequencing, quantitative PCR,
Southern blot, multiplex ligation-dependent probe amplification
and genome-wide single nucleotide polymorphism microarrays
(Katsanis and Katsanis, 2013). It is important to note that
when biochemistry analyses are positive, revealing nucleoside
accumulation and loss of thymidine phosphorylase function,
Sanger sequencing is advisable. However, in case of doubtful
biochemical profiling or negative detection of TYMP variants
by Sanger sequencing, gene panels, whole exome sequencing
(WES), whole genome sequencing (WGS) or mtDNA studies are
recommended for the identification of MNGIE-like disorders.
Examination of mtDNA using Southern blot analysis has
revealed abnormalities, including those which are quantitative
(depletions) and qualitative (multiple deletions and point
mutations) (Hirano et al., 1994; Papadimitriou et al., 1998;
Nishino et al., 2000). An uneven distribution of mtDNA
abnormalities (depletion, single nucleotide variants, deletions,
duplication) along the nerves is hypothesized to be the cause
of segmental demyelination. MtDNA depletion, mitochondrial
proliferation, and smooth cell atrophy have been shown in the
external layer of the muscularis propria in the stomach and small
intestine (Giordano et al., 2006, 2008).
Clinical Examination
Currently the diagnosis is initially suspected based on clinical
signs of gastrointestinal dysmotility, cachexia, peripheral
neuropathy and ophthalmoplegia (Nishino et al., 2000; Garone
et al., 2011). It is noteworthy that these clinical evaluations are
not specific to the disease but are rather a general approach
used for patients to assist in raising the suspicion of MNGIE.
Audiologic, ophthalmologic evaluation and gastroenterology
examinations such as abdominal CT, upper gastrointestinal
tract contrast radiography, esophagogastroduodenoscopy,
sigmoidoscopy, liquid phase scintigraphy and antroduodenal
manometry are supportive for the diagnosis of MNGIE (Mueller
et al., 1999; Teitelbaum et al., 2002; Halter et al., 2010).
MRI
Progressive and diffuse leukoencephalopathy is invariably
observed in brain MRI of MNGIE patients, visualized as
described above. Therefore, MRI is often used to evaluate
one of the main clinical criteria of MNGIE. White matter
MRI abnormalities provide a clear indication of the disease
and in its absence MNGIE disease is very unlikely (Scarpelli
et al., 2013). In fact, leukoencephalopathy helps discriminate
between MNGIE and pseudo-MNGIE presentations of other
disorders (Hirano et al., 2004b). However, a case study of
patients with POLG mutations has been documented which
present MNGIE-like phenotype exhibiting leukoencephalopathy
on MRI, which is not a typical observation in these type of
patients (Yasuda et al., 2018). One study also showed mild
cortical atrophy and oculomotor and trigeminal nerve signal
enhancement in T1 sequences (Petcharunpaisan and Castillo,
2010). Similarly, another study reported supratentorial cortical
atrophy in patients with MNGIE (Barragán-Campos et al., 2005).
Magnetic resonance spectroscopy (MRS) studies have also shown
reduction in choline and N-acetyl aspartate indicating axonal
loss and glial cells loss (Schupbach et al., 2007). However, in a
recent study by Gramegna et al., MRS of patients with MNGIE
has shown a consistent reduction of all metabolites in the white
matter although their ratio to creatine remained in the normal
range. This finding, combined with the increased radial water
diffusivity in images, is suggestive of increases in water content
which could be attributable to a possible increase in the BBB
permeability rather than neural cell loss (Gramegna et al., 2018).
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Electrodiagnostic Procedures
Electrodiagnostic procedures are valuable to confirm
neuromuscular dysfunctions, which are one of the major clinical
criteria for MNGIE. Neurogenic and myogenic abnormalities are
commonly detected on electromyography. Nerve conductions
studies typically show decrease in motor and sensory nerve
conduction velocities and prolonged F-wave (Hirano et al.,
2004b).
Biochemical Findings
Routine clinical biochemical studies do not provide specific clues
to a diagnosis of for MNGIE, although these are helpful to
corroborate features that are common in patients including lactic
acidosis, indicative of an oxidative phosphorylation defect (Martí
et al., 2004). Furthermore, mild elevation in serum lactic acid and
serum pyruvate have been reported, as well as elevation in uric
acid, lactate dehydrogenase and creatine kinase (Hirano et al.,
1994; Teitelbaum et al., 2002). Increased levels of cerebrospinal
fluid lactate and total protein have been described (Teitelbaum
et al., 2002; Röeben et al., 2017). Severe hypokalaemia was also
observed in two patients leading to muscle tetany and cardiac
arrythmia (Garone et al., 2011).
PRE-CLINICAL EXPERIMENTAL MODELS
In vitro and in vivo models of MNGIE have been developed to
enhance the understanding of the disease pathogenesis and the
development of experimental therapies, Table 2.
In vitro Models
There is a paucity of specific in vitromodels of MNGIE described
in the literature. A majority of the cell types implemented
to date have no relevance to the organ systems affected
in MNGIE and were used mainly to understand the effect
of deoxyribonucleoside pool imbalances on cellular functions
(Rampazzo et al., 2000, 2004; Pontarin et al., 2003). The
first model developed was by Spinazzola et al. (2002), where
fibroblasts derived from healthy controls and patients with
MNGIE were used to study the contribution of thymidine
phosphorylase in the deoxyribonucleoside pool imbalances.
They examined the culture medium of cultured fibroblasts to
determine the ability of healthy control cells and MNGIE patient
cells to metabolize thymidine; in contrast to healthy cells, where
a decline in media thymidine concentrations was measured,
MNGIE fibroblasts were not able to catabolize thymidine,
resulting in an increase in culture medium thymidine levels
(Spinazzola et al., 2002).
Nishigaki et al. (2003) employed MNGIE-derived fibroblast
to further evaluate the role of dysfunctional thymidine
phosphorylase in the accumulation of deoxyribonucleoside
pools (both thymidine and deoxyuridine) and with consequent
mtDNA damage. Using patient-derived cell lines, 36 mtDNA
point mutations, a TT to AA substitution and a single nucleotide
deletion were identified. In MNGIE fibroblast cultures,
cyclooxygenase activity was decreased, whereas deoxyuridine
levels were markedly elevated. Also, an elevation in reactive
oxygen species was observed, which was proposed to be a
contributing factor to the accumulation of mtDNA point
mutations. MtDNA sequencing of cultured fibroblasts and post
mortem biopsies of skeletal muscle cells revealed a higher level
of mtDNA point mutations in fibroblasts, whereas multiple
mutations and deletions were observed at low levels in skeletal
muscles. This suggests that fibroblasts primarily depend on
anaerobic glycolysis rather than oxidative phosphorylation
and therefore the absence of pressures on defective respiratory
chain complexes in mitochondria results in the accumulation
of nucleotide pools that generates a higher number of point
mutations (Nishigaki et al., 2003).
In 2003, Song et al. used HeLa cells to show that increases
in thymidine levels lead to an imbalance in dNTP pools,
which ultimately result in mtDNA mutations. HeLa cells were
cultured in medium supplemented with 50µM thymidine.
After 4 h of growth in thymidine-supplemented medium,
the mitochondrial deoxythymidine triphosphate (dTTP) and
deoxyguanosine triphosphate (dGTP) pools were shown to
expand, whereas the deoxycytidine triphosphate (dCTP) pool
dropped significantly, and the dATP pool dropped slightly. In
whole cell extracts, the dTTP and dGTP pools also expanded, the
dCTP pool decreased by approximately 50%, and the dATP pool
remained unchanged. These changes in mitochondrial dNTP
pools are consistent with a mutagenic mechanism involving the
T-G mispairing followed by a next-nucleotide effect involving
T insertion opposite to A. Supplementation of HeLa cells for
8 months with 50µM thymidine, resulted in several mtDNA
deletions (Song et al., 2003). It is noteworthy that to recreate
MNGIE metabolite accumulations, the study implemented a 2.5-
fold higher thymidine concentration to that observed in MNGIE
patients, which is typically 20µM thymidine (Song et al., 2003;
Ferraro et al., 2005).
In 2005, Ferraro et al. conducted a similar experiment
to Spinazzola et al. (2002), but used healthy skin and lung
quiescent fibroblasts to demonstrate that mtDNA depletions
are associated with post-mitotic cells. The study identified
that mitochondrial deoxynucleotides are synthesized by two
independent salvage pathways. In cycling cells, thymidine is
salvaged by cytosolic thymidine kinase 1 (TK1) whereas in
quiescent cells, thymidine is phosphorylated via thymidine
kinase 2 (TK2) in the mitochondria, and the thymidine
diphosphates then exported to the cytosol. Both cytosolic and
mitochondrial thymidine phosphates undergo rapid turnover via
deoxythymidine monophosphate (dTMP)/ thymidine substrate
cycles. Therefore, quiescent cells lacking de novo synthesis
and TK1 create a bias in dTTP pools, and this is further
exacerbated in MNGIE where thymidine phosphorylase is
lacking. Ferraro et al. (2005) cultured quiescent fibroblasts in
medium supplemented with 10–40µM thymidine and observed
intra-cytosolic and intra-mitochondrial increase in dTTP and
uridine triphosphates, both contributing to mtDNA depletions,
concluding that mitochondrial DNA damage in MNGIE is
predominant in post-mitotic cells (Ferraro et al., 2005).
González-Vioque et al. (2011), made use of murine liver
mitochondria to show that mtDNA depletions are a consequence
of a limited dNTP availability rather than a dNTP imbalance
itself. The study demonstrated that excess of thymidine results
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in an increase of dTTP concentrations in mitochondria due to
TK2 activity, with consequent secondary depletion of dCTP.
TK2 phosphorylates both thymidine and cytidine competitively;
each deoxynucleotide modulates the enzyme to consequently
inhibit the phosphorylation of the other, although thymidine is
more efficient at inhibiting the phosphorylation of cytidine. The
addition of dCTP or deoxycytidine restored mtDNA depletions
even in the presence of thymidine overload, confirming that
mtDNA depletions are the result of a limited availability of
substrates formtDNA replication, caused by nucleotide depletion
consequent to nucleotide overload rather than thymidine excess
alone (González-Vioque et al., 2011).
Overall, in vitro models developed so far, have been
informative and relevant for the understanding of the underlying
biochemical and molecular mechanisms, associated with the
deoxyribonucleoside pool imbalances and mtDNA depletions.
However, to date tissue-specific models using cells relevant to the
CNS, PNS and enteric system have not been developed and thus
the study of alternative implications for the lack of thymidine
phosphorylase expression on other biological pathways,
including nervous tissue development and maintenance, has not
been fully addressed.
Our research group has developed for the first time a MNGIE
iPSC line which was used to generate a cerebral organoid
model for the study of the CNS pathomolecular mechanisms
and provide elucidations on the leukoencephalopathy observed
(Pacitti, 2018; Pacitti and Bax, in press).
In vivo Models
Murine models have proved to be very efficacious in the study
of MNGIE, though it is important to consider the significant
biological and hence metabolic differences between rodents and
humans. This is exemplified by the metabolism of thymidine
in the mouse, which is not only phosphorylated by thymidine
phosphorylase, but also by uridine phosphorylase 1 and uridine
phosphorylase 2; in the human, thymidine is solely metabolized
by thymidine phosphorylase (el Kouni et al., 1993). To address
this, Haraguchi et al. (2002) established a murine model based
on double knock-out of Tymp−/−/Upp1−/− genes, whilst uridine
phosphorylase 2 is not knocked-out in this model. Although
this model recapitulates some features of the disease, it also
displays some incongruences with the clinical scenario. The
knock-out animals have a 10-fold increase in plasma thymidine
and deoxyuridine, compared to>100-fold increase in the human.
The mice also show cerebral oedema with hyperintense T2 MRI
regions and axonal myelin fiber dilation without demyelination,
however no peripheral neurological abnormalities were observed
(Haraguchi et al., 2002). Also, Haraguchi et al. (2002) did not
detect any mtDNA abnormalities in brain and muscle tissues
of mice, suggesting that the loss of function of thymidine
phosphorylase alone is not sufficient to cause MNGIE in this
model. This led to the hypothesis that the adjacent gene SCO2
overlapping with TYMP sequences may be also contributing
to the disease. The lack of mtDNA depletion in mice may be
the result of a difference in mtDNA repair and replication, by
which an increase in thymidine concentration may not affect the
mitochondria of mice as it does in humans (Haraguchi et al.,
2002).
A second double knock-out murine model of MNGIE was
created in 2009 by Lopez et al. to characterize the biochemical,
genetic and histological features of MNGIE in mice, and translate
findings into the clinical picture (López et al., 2009). The
resulting mice displayed undetectable thymidine phosphorylase
activity in all tissues except in the liver, where the residual
17% activity was attributed to the expression of uridine
phosphorylase 2. Mice displayed a 4- to 65-fold increase in
thymidine levels in all tissues, with partial mtDNA depletions.
Similarly, to the model developed by Haraguchi et al. (2002), the
rodents manifested cerebral oedema with hyperintense T2 MRI
signals in white matter, and late-onset cerebral and cerebellar
white matter vacuoles without demyelination or axonal loss.
However, in contrast to MNGIE patients, the model displayed
mtDNA depletion, respiratory chain defects and histological
abnormalities only in the brains, without any gastrointestinal or
skeletal muscle involvement. López et al. (2009) suggested that
the selective cerebral involvement observed in mice is possibly
due to a number of factors, including differences in the life-
span between species, as mice may not live long enough to
accumulate sufficient mtDNA damage in most tissues or because
the deoxyribonucleoside imbalance in humans is substantially
more dramatic than in mutant mice. A third explanation is
that high expression of TK2 in quiescent neuronal cells of
rodent brains may contribute to an increased TTP production,
thereby accelerating mtDNA damage in nervous tissues (Rylova
et al., 2007). With regard to the contrasting findings of mtDNA
depletions between Haraguchi’s and Lopez’s model, this could
be explained by limitations in the analytical methods used for
evaluating mtDNA aberrations (López et al., 2009).
In 2014, Garcia-Diaz et al. conducted a study to confirm the
hypotheses generated by López et al. (2009) with regard to the
role of thymidine accumulation in the pathogenesis of MNGIE,
and in particular in the gastrointestinal involvement. López et al.
(2009) failed to recapitulate the gastrointestinal dysmotility in
mutant mice, and only replicated certain pathological features in
mouse brains. It was speculated that themild phenotype observed
in the model is attributable to the short life-span of the animals
combined with the modest increase in deoxyribonucleoside
accumulation produced by mutant mice (which was 45-fold
lower than that observed inMNGIE patients). Thus, to overcome
this, Garcia-Diaz et al. (2014) supplemented mutant mice
with exogenous thymidine and deoxyuridine to recreate a
similar disproportion of deoxyribonucleoside concentrations
as observed in humans, recapitulating the >100-fold increase
in thymidine concentrations. The prolonged supplementation
of deoxyribonucleosides in mutant mice resulted in the
acquisition of biochemical abnormalities in the brain and small
intestine, including mitochondrial DNA depletion as evidenced
by cyclooxygenase deficiency observed through histological
evaluations. Overall, treating double knock-out mice with
thymidine was sufficient to enhance the phenotype of the
model to recapitulate the clinical features of MNGIE, including
weight loss, small intestine muscularis propria pathology,
muscle weakness, leukoencephalopathy and decreased survival
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(Garcia-Diaz et al., 2014). However, in contrast to patients
with MNGIE, who have multiple mtDNA deletions in brain,
muscles, kidney and liver, the brain and muscle of 24-month
old treated and untreated wild-type and Tymp−/−/Upp1−/−
mice demonstrated similar levels of deleted mtDNA, suggesting
that this is most likely due to aging rather than thymidine
phosphorylase deficiency (Garcia-Diaz et al., 2014). Differences
in the deoxyribonucleoside metabolism between humans and
mice indicates the inadequacy of this model in recapitulating
the human disease (Haraguchi et al., 2002; López et al., 2009;
Garcia-Diaz et al., 2014).
TREATMENT OPTIONS
Disease Management
Currently, there are no specific therapies for patients with
MNGIE whose effectiveness has been evidenced in clinical trial
studies. The current disease management guidelines aims to treat
the specific symptoms that are evident in each individual and
invariably requires the co-ordinated effort of different clinical
specialities. Abdominal pain and nausea/vomiting secondary
to gastrointestinal dysmotility are almost invariable, with
patients treated symptomatically with analgesics, bowel motility
stimulant drugs, anti-emetics and antibiotics for intestinal
bacterial overgrowth (Teitelbaum et al., 2002; Oztas et al.,
2010). Domperidone may be administered to control the post-
prandial emesis and nausea (Yavuz et al., 2007). The reduction of
epigastric pain episodes, especially in patients that are refractory
to opiate pain management, can be achieved by performing
a celiac plexus block with bupivacaine or by the selective
blockade of the splanchnic nerve (Teitelbaum et al., 2002;
Celebi et al., 2006). Pain may also occur in the limbs due to
peripheral polyneuropathy and this can be treated with centrally
acting agents such as amitriptyline, gabapentin and pregabalin
(Hafez et al., 2014; Finsterer and Frank, 2017). Patients with
MNGIE have an increased incidence of perforation of the gut,
which generally requires emergency abdominal surgery (Granero
Castro et al., 2010).
Malnutrition is a major problem in the majority of patients;
various forms of parenteral nutrition, including total parenteral
nutrition, are frequently required, but do not modify outcome
(Wang et al., 2015). Complications of long-term parenteral
nutrition use include the development of hepatic steatosis and
cholestasis, and triglyceride hyperlipidemia. For patients with
MNGIE there is the risk of metabolic oversupply from the
lipid and carbohydrate components of the parenteral nutrition,
leading to further mitochondrial toxicity. In later stages of
the disease, patients are often unable to tolerate nasogastric
nutrition due to gastrointestinal dysmotility (Wang et al., 2015).
Portal hypertension may occur and be complicated by ascites
and esophageal varices (Moran et al., 2008). These conditions
are treated in the same way as when they occur in other
conditions. Drugs that interfere with mitochondrial function
should be avoided and hepatically metabolized drugs should be
administered with care or contraindicated depending on the
patient’s liver function (Halter et al., 2010). Physiotherapy and
occupational therapy input is usually required, particularly to
address the neurological aspects of the condition.
Investigational Therapies
A number of experimental therapeutic approaches are currently
under investigation, including haemodialysis and peritoneal
dialysis (Spinazzola et al., 2002; la Marca et al., 2006;
Yavuz et al., 2007), allogeneic haematopoietic stem cell
transplantation (AHSCT) (Hirano et al., 2006; Halter et al.,
2010; Filosto et al., 2012), platelet transfusion (Lara et al.,
2006), orthotopic liver transplant (OLT) (De Giorgio et al.,
2016) and enzyme replacement (Bax et al., 2013). The
therapeutic strategy common to all these approaches is
to reduce or eliminate the pathological concentrations of
thymidine and deoxyuridine, thereby ameliorating intracellular
deoxyribonucleoside imbalances and preventing further damage
to mtDNA, thus translating into clinical stabilization or
improvement.
Plasma concentrations of thymidine were shown to be
transiently lowered by haemodialysis, and infusions of platelets,
which contain thymidine phosphorylase, were shown to reduce
circulating levels of thymidine and deoxyuridine in two patients
(Lara et al., 2006; Röeben et al., 2017). Disadvantages of these
approaches are that haemodialysis is a burdensome procedure
and long-term platelet therapy carries risks of developing
immune reactions and transmission of viral infections and the
short duration of effect.
AHSCT offers the possibility of a permanent correction
of the thymidine phosphorylase deficiency but is limited by
the availability of a matched donor. Patients are often in a
poor clinical condition with an impaired capacity to tolerate
transplant related problems and the aggressive conditioning and
immunosuppressive chemotherapy (Halter et al., 2010, 2015).
AHSCT also presents pharmacological challenges in terms of
administering drugs with possible mitochondrial toxicity, and
the requirement for parenteral administration due to disturbed
gastrointestinal function and impairment of absorption. A
published consensus proposal for standardizing an approach to
AHSCT in patients with MNGIE recommended a recruitment
restriction to patients in a stable clinical condition without
irreversible end stage disease and having optimal donor (Halter
et al., 2010). AHSCT is associated with an elevated mortality risk
due to host-vs. -graft reactions and hospital acquired infections
caused by the aggressive immunosuppressive regimen, combined
with the disease (Halter et al., 2010; Filosto et al., 2012; Peedikayil
et al., 2015). Halter et al. (2015) reported a mortality of 62.5%
after the follow-up of 24 patients who received AHSCT (Halter
et al., 2015). Patients who are oligosymptomatic are often
reluctant to undergo AHSCT due to its high morbidity and
mortality risk. A recent study suggested that the effect of AHSCT
may be transient (Baker et al., 2017). Furthermore, a study
focusing on the neuromuscular pathology of the small intestine
inMNGIE highlighted that AHSCTmay be insufficient to restore
integrity of the enteric neurons and glia, thus without any short-
term impact on the neurogenic and myogenic intestinal changes
observed in later stages of MNGIE (Yadak et al., 2018a).
Frontiers in Genetics | www.frontiersin.org 14 December 2018 | Volume 9 | Article 669
Pacitti et al. A Review of Mitochondrial Neurogastrointestinal Encephalomyopathy
Due to the elevated expression of thymidine phosphorylase in
the liver, solid organ transplantation is considered an alternative
long-term therapeutic option (Boschetti et al., 2014). A case
study has shown that OLT was able to normalize metabolite
levels and provide mild improvements of neurological symptoms
(De Giorgio et al., 2016; D’Angelo et al., 2017). The extent
to which tissue damage can be reversed through the clearance
of deoxyribonucleoside imbalances post- OLT has yet to be
determined (De Giorgio et al., 2016).
Enzyme replacement therapy using autologous erythrocyte-
encapsulated thymidine phosphorylase (EETP) is under
investigation and has Orphan drug Designation by the FDA
and EMA. The rationale for the development of EETP is based
on thymidine and deoxyuridine being able to freely diffuse
across the erythrocyte membrane via nucleoside transporters
into the cell where the encapsulated enzyme catalyses their
metabolism to the normal products (Figure 6). The products are
then free to exit the cell into the blood plasma where they are
further metabolized as normal. EETP is directed at ameliorating
thymidine and deoxyuridine levels to slow the progression of
MNGIE and stabilize the clinical condition and could therefore
increase the chance of eligibility for AHSCT or OLT once a match
is identified. Encapsulation of enzyme within the erythrocyte has
the pharmacological advantages of prolonging the circulatory
half-life of the enzyme and potentially minimizing immunogenic
reactions which are frequently observed in enzyme replacement
therapies administered by the conventional route. To date
five patients have received EETP under a compassionate use
programme, where clinical and metabolic improvements were
observed (Moran et al., 2008; Halter et al., 2010; Godfrin and
Bax, 2012; Godfrin et al., 2012; Bax et al., 2013).
Promising gene therapies for MNGIE are also under
experimentation in murine models, using adenoviral vectors
(AVV) targeting the liver for the correction of TYMP mutations
for the restoration of normalized nucleoside metabolism
(Torres-Torronteras et al., 2014). More recently, pre-clinical
investigations of hematopoietic stem cell gene therapy in murine
models have been conducted (Torres-Torronteras et al., 2016;
Yadak et al., 2018a,b). A timeline of all investigational therapeutic
approaches is summarized in Figure 7.
Clinical Efficacy Endpoints
The development of drugs for rare diseases is confounded
by a number of challenges such as small patient populations,
phenotypic heterogeneity, incomplete knowledge of the disease
pathophysiology or natural history and an absence of prior
clinical studies. Consequently, the selection of clinical efficacy
endpoints, which assess the way a patient feels, functions, or
survives, can be an arduous process, particularly as validated
endpoints appropriate for the disease are often unavailable.
There are generally no accepted endpoints for clinical studies
in patients with MNGIE. This ultra-rare disease presents with
usually a combination of cachexia, gastrointestinal dysfunction,
and neuromuscular dysfunction. The determinants of morbidity
and mortality in patients with MNGIE cannot be easily
ascertained and owing to the rarity of the disease, there is no
authoritative literature on the topic. The available case series
of patients with MNGIE are small and with limited follow-up;
the heterogeneity of the sources further limits the possibility
to collate this information objectively. Additionally, there are
no established patient reported outcomes specific to MNGIE.
The experimental treatments for MNGIE aim to reverse the
biochemical imbalances by eliminating the elevated systemic
concentrations of thymidine and deoxyuridine. However, these
metabolites do not provide objective measurements correlated
to clinical status and are thus not suitable as end-points
for predicting clinical benefit of therapeutic strategies. Several
patients reported outcomes are available for specific symptoms
FIGURE 6 | Mechanism of EE-TP action. Plasma thymidine and deoxyuridine enter the erythrocyte via nucleoside transports located in the cell membrane, where the
encapsulated thymidine phosphorylase catalyses their metabolism to thymine and uracil. The products are then free to diffuse out of the cell into the blood plasma
where they can enter the normal metabolic pathways.
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FIGURE 7 | Timeline of pre-clinical and clinical investigational therapeutic approaches for MNGIE.
or groups of symptoms (e.g., gastrointestinal, neuropathic) which
are highly prevalent in patients with MNGIE; however, the extent
to which those measurement instruments would be applicable to
patients with MNGIE is unknown.
Despite genotypic differences and a variable phenotype,
gastrointestinal symptoms including early satiety, nausea,
dysphagia, gastroesophageal reflux, postprandial emesis, episodic
abdominal pain, episodic abdominal distention, and diarrhea
are cardinal manifestations of MNGIE and severely compromise
nutritional homeostasis in almost all patients, leading to weight
loss and cachexia. One of the largest case series available reports
a “thin” body habitus in all patients, with weight loss from
diagnosis averaging 15.2 kg (range: 5.9–30.0 kg) (Nishino et al.,
1999).
Although clinicians treating patients with MNGIE,
unanimously agree that weight loss is the key feature of
the disease and has a major impact on their functional
status, individual weight loss trajectories are not typically
available in published case series. The consensus in personal
communications with clinicians who treat those patients
suggests that patients with MNGIE relentlessly lose weight and
that this has a major impact on their functional status. Anecdotal
evidence based on a review of case series and case studies in the
literature suggests that organ failure, hepatic and gastrointestinal
complications associated to cachexia are frequent causes of death
in patients with MNGIE (Nishino et al., 2000; Garone et al.,
2011).
The collection of uniform observational data through
the operation of patient registries is one approach that is
employed to identify suitable efficacy endpoints. Registries are
particularly relevant to the field of rare diseases where the
disorder has a heterogeneous presentation and information on
the natural history is scarce. Of relevance to patients with
MNGIE is the Rare Disease Clinical Research Network Natural
History Study of MNGIE (NCT01694953) and also the North
American Mitochondrial Disease Consortium which is currently
collecting medical and family history, diagnostic test results,
and prospective medical information; information from this will
be invaluable for supporting the evaluation of new treatment
modalities.
The Regulatory agencies are now recognizing the need for
flexibility in the review of therapies for rare diseases and may
consider approving a therapy based on a surrogate endpoint
or biomarker as these can provide better objective measures
of clinical benefit. Based on the identification of a number of
dysregulated miRNAs in the serum of patients with MNGIE
compared to age and sex matched healthy controls, Levene et al.
are examining the application of a miRNA panel as a surrogate
end-point biomarker in parallel with a clinical trial of EETP
(Levene et al., in press).
PROGNOSIS
MNGIE is a relentlessly progressive degenerative and terminal
disorder with a poor prognosis. The estimated mean age of
mortality is 37.6 years, with a range of 26–58 years (Nishino et al.,
2000). Garone et al. reports the use of a Kaplan-Meier analysis, as
a valuable instrument to give a reliable prognosis, thus providing
the most updated estimates in term of life expectancy to date,
indicating that in MNGIE survival lies between 20 and 40 years
of age. Common causes of death include malnutrition, metabolic
acidosis, aspiration pneumonia, intestinal perforation, peritonitis
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and complications aroused by bacterial overgrowth (Filosto et al.,
2011; Garone et al., 2011).
EXTERNAL RESOURCES FOR CLINICIANS
AND PATIENTS
Below we present a list of resources for clinicians and patients:
https://www.omim.org/entry/603041
https://rarediseases.org/rare-diseases/mitochondrial-
neurogastrointestinal-encephalopathy/
https://clinicaltrials.gov/ct2/show/NCT01694953
https://www.mitocon.it/classificazione-genetica-delle-
malattie-mitocondriali/
https://ghr.nlm.nih.gov/condition/mitochondrial-
neurogastrointestinal-encephalopathy-disease
https://www.orpha.net/
www.telethon.it
http://www.pumpa.org.uk/
https://www.thelilyfoundation.org.uk/
http://www.umdf.org/
http://www.mitoaction.org/
CONCLUDING REMARKS
MNGIE is a metabolic disorder with an invariably fatal
outcome. In the last 40 years since the first description
of MNGIE, considerable progress has been made in the
elucidation of the pathogenic mechanisms that underlie this
ultra-rare disease. The wealth of knowledge available enabled
the canonical and the sporadical features of the pathology to
be clearly defined, permitting explicit diagnostic criteria and
approaches to be determined. Recently, Zimmer et al. proposed
an algorithm for the clinical diagnosis of MNGIE, whereby
patients exhibiting suggestive clinical symptoms, such as eye
movement disorder, are recommended to undergo cerebral
MRI investigations. If leukoencephalopathy is then detected, the
algorithm suggests biochemical testing for metabolite excess in
biofluids, followed by the sequencing of the TYMP gene, should
an accumulation of thymidine and deoxyuridine be identified
(Zimmer et al., 2014). It is important to highlight however,
that MNGIE, as for many other mitochondrial disorders
lacks of a prospective natural history study, although one is
currently ongoing and pending results. In this respect patient
stratification, still remains a substantial challenge. Nevertheless,
the advent of NGS, has certainly changed the diagnostic approach
toward mitochondrial diseases, including MNGIE, thus reliably
improving the screening and clustering of patients. Therefore,
in many cases a shift in diagnostic methodologies is observed
toward a direct genetic screening (Calvo et al., 2012; Carroll
et al., 2014; Craven et al., 2017; Kremer et al., 2017). On
the other hand, NGS has not entirely replaced the use of the
first line investigations for the identification of MNGIE, i.e.,
quantifying thymidine and deoxyuridine in plasma and urine. In
fact, recent research efforts have been directed at improving the
analytical methods used. For instance, optimized and validated
methods aimed at simplifying the chromatographic conditions
and reducing analytical errors for the quantification of thymidine
and deoxyuridine in urine and plasma of MNGIE patients, was
developed and compared with previously reported analytical
methods (Mohamed et al., 2014; Sun, 2016). It is noteworthy
that advancements in experimental therapies for MNGIE are
mostly of recent development; indeed, the first published data
collection of all patients treated with AHSCT dates back to 2015,
sixteen years after the mutation was first identified (Halter et al.,
2015). It is also important to note, that predominantly in eastern
countries, the most dated therapeutic approach, more specifically
peritoneal dialysis and haemodialysis, are still being used in
the management of MNGIE (Sivadasan et al., 2016; Chandra
et al., 2018). A number of experimental therapies are currently
under development with the aim of rescuing the phenotype by
restoring homeostatic thymidine phosphorylase activity and/or
normalizing systemic deoxyribonucleoside accumulations. Most
notably, a recent study conducted by Torres-Torronteras et al.,
describes a novel promising pre-clinical investigation regarding
the long-term efficacy of AVV gene therapy in MNGIE (Torres-
Torronteras et al., 2016). However, there is still a substantial gap
between pre-clinical trials and the translation of novel treatments
into humans. Furthermore, the rarity of the condition and the
absence of a natural history study hinders the identification
of reliable end-points, further complicating the progression
of experimental therapies. In this respect, MNGIE benefits
from clinical interest because is one of the few treatable rare
mitochondrial disorders (Filosto et al., 2018). With the up and
coming clinical trials of these novel therapeutic approaches,
including the enzyme replacement therapy under investigation
by our group, we believe this comprehensive review will
guide and inform clinicians of the intricacies of this rare
and fatal disorder, thereby expediting disease diagnosis and
treatment access to patients earlier on in the disease process.
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